Cascadian Therapeutics (ONTY) 10-Q 2010 Q3 Quarterly report

Exhibit 12.1

Oncothyreon Inc. and Consolidated Subsidiaries

Statement Regarding Computation of Ratio of Earnings to Fixed Charges

	For the Nine
	Months Ended
	September 30,
	2009
Earnings before fixed charges:
Income/(loss) from continuing operations before income taxes, minority interest and income/(loss) from equity investees	$	(9,464	)
Add fixed charges		21
Add amortization of capitalized interest		—
Add distributed income of equity investees		—
Subtract capitalized interest		—
Income/(loss) before fixed charges	$	(9,443	)
Fixed charges:
Interest expense	$	—
Amortization of debt expense		—
Estimate of interest expense within rental expense		21
Preference security dividend requirements of consolidated subsidiaries		—
Total fixed charges	$	21
Deficiency of earnings available to cover fixed charges	$	(9,464	)